Closing the data loop in AI-driven drug discovery

MIT Technology Reviewby MIT Technology Review Insightstech

Drug discovery is a high-cost, high-risk endeavor that is under growing pressure from a market increasingly defined by first-mover advantage. Since the 1950s, the cost of developing new pharmaceuticals has roughly doubled every nine years—a phenomenon known as Eroom’s Law. Today, bringing a new drug to market takes an average of 10-15 years and costs…

This article was published on MIT Technology Review (technologyreview.com). Read the full article on the original source:

Read full article on MIT Technology Review

More from MIT Technology Review